These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 34497100)

  • 1. Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
    Weber MS; Nicholas JA; Yeaman MR
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34497100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
    Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
    Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R; Oh J
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
    McCulloch R; Eyre TA; Rule S
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):923-939. PubMed ID: 32861287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton Tyrosine Kinase Inhibitors: Present and Future.
    Burger JA
    Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma.
    Luo W; Li C; Wu J; Tang L; Wang X; Zhang Y; Wu Z; Huang Z; Xu J; Kang Y; Xiong W; Deng J; Hu Y; Mei H
    Cytotherapy; 2023 Jul; 25(7):739-749. PubMed ID: 37074239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of ibrutinib in COVID-19 hyperinflammation: A case report.
    Maynard S; Ros-Soto J; Chaidos A; Innes A; Paleja K; Mirvis E; Buti N; Sharp H; Palanicawandar R; Milojkovic D
    Int J Infect Dis; 2021 Apr; 105():274-276. PubMed ID: 33607304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
    Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
    Sestier M; Hillis C; Fraser G; Leong D
    Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.
    Torke S; Weber MS
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1143-1150. PubMed ID: 32772592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase inhibition for the treatment of allergic disorders.
    Lin EV; Suresh RV; Dispenza MC
    Ann Allergy Asthma Immunol; 2024 Jul; 133(1):33-42. PubMed ID: 38492772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
    Krämer J; Wiendl H
    Curr Opin Neurol; 2024 Jun; 37(3):237-244. PubMed ID: 38533819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
    Mhibik M; Wiestner A; Sun C
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.
    Aghel N; Baro Vila RC; Lui M; Hillis C; Leong DP
    Curr Cardiol Rep; 2023 Sep; 25(9):941-958. PubMed ID: 37498449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.
    Zhang L; Gao YH; Li SY; Zhao H; Zhang MY; Yu YY; Liu YT; Li J
    Int J Hematol; 2024 Jun; 119(6):631-637. PubMed ID: 38546960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect.
    Wang H; Guo H; Yang J; Liu Y; Liu X; Zhang Q; Zhou K
    Exp Hematol Oncol; 2022 Sep; 11(1):60. PubMed ID: 36138486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
    Pleyer C; Ali MA; Cohen JI; Tian X; Soto S; Ahn IE; Gaglione EM; Nierman P; Marti GE; Hesdorffer C; Lotter J; Superata J; Wiestner A; Sun C
    Blood; 2021 Jan; 137(2):185-189. PubMed ID: 33259596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis.
    Proskuriakova E; Shrestha DB; Jasaraj R; Reddy VK; Shtembari J; Raut A; Gaire S; Khosla P; Kadariya D
    Clin Ther; 2024 Feb; 46(2):134-145. PubMed ID: 38102000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
    Bond DA; Maddocks KJ
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.